Cargando…
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
PURPOSE: In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer. PATIENTS AND METHODS: Patients with advanced gastric cancer who had been previously treated wi...
Autores principales: | Shitara, Kohei, Hirao, Motohiro, Iwasa, Satoru, Oshima, Takashi, Komatsu, Yoshito, Kawazoe, Akihito, Sato, Yasuyoshi, Hamakawa, Takuya, Yonemori, Kan, Machida, Nozomu, Yuki, Satoshi, Suzuki, Takuya, Okumura, Shiori, Takase, Takao, Semba, Taro, Zimmermann, Bob, Teng, Angela, Yamaguchi, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102841/ https://www.ncbi.nlm.nih.gov/pubmed/36730323 http://dx.doi.org/10.1158/1078-0432.CCR-22-3027 |
Ejemplares similares
-
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022) -
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023) -
Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer
por: Udagawa, Hibiki, et al.
Publicado: (2022) -
Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020) -
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)